Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma

Zachary Whitham; David Hsiehchen

doi:10.1016/j.soc.2023.07.003

Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma

Surg Oncol Clin N Am. 2024 Jan;33(1):87-97. doi: 10.1016/j.soc.2023.07.003. Epub 2023 Aug 31.

Authors

Zachary Whitham¹, David Hsiehchen²

Affiliations

¹ Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
² Department of Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA. Electronic address: David.hsieh@utsouthwestern.edu.

PMID: 37945147
DOI: 10.1016/j.soc.2023.07.003

Abstract

Immunotherapy has revolutionized the standard of care in multiple aspects of oncology. Given successes in the setting of unresectable hepatocellular carcinoma (HCC) and the advantages of neoadjuvant therapy, many trials are demonstrating the safety and feasibility of combination of immune checkpoint inhibitors (ICIs)/tyrosine kinases in patients with resectable HCC. Numerous clinical trials are currently investigating the role of different immune modulators either as monotherapy or as combination therapy in the neoadjuvant setting. Key questions that remain to be addressed include efficacy, safety, predictive biomarkers, and length of treatment.

Keywords: Hepatocellular carcinoma; Immune checkpoint inhibitors; Immunotherapy; Neoadjuvant systemic therapy.

Publication types

Review

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / surgery
Combined Modality Therapy
Humans
Immunotherapy
Liver Neoplasms* / drug therapy
Liver Neoplasms* / surgery
Neoadjuvant Therapy